

THURSDAY
5th JUNE
2025

afpbn

ASSOCIATION FRANÇAISE
DE PSYCHIATRIE BIOLOGIQUE
NEUROPSYCHOPHARMACOLOGIE

afpbn
section
médecine
psychédélique

PSYCHEDELIC MEDICINE: SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

Organizing Committee :

Dr. Lucie Berkovitch

Dr. Hugo Bottemanne

Prof. Luc Mallet

Dr. Bruno Roméo

All presentations will be delivered in English only, with no live translation available.
Please note that no replay is currently scheduled.

ICM - Institut du Cerveau

Hôpital Pitié-Salpêtrière

47 bd de l'Hôpital, 75013 Paris

Soutenu
par le



GOUVERNEMENT

Liberté
Égalité
Fraternité

MILDECA

Mission interministérielle
de lutte contre les drogues
et les conduites addictives

PSYCHEDELIC MEDICINE: SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

8:45 AM: Welcome

9:00 AM: Introduction - Bureau of the Psychedelic Medicine Section

09:15–10:00 AM: Pharmacology of psychedelics: similarities and differences - Matthias Liechti, Basel University

Chair : Carine Becamel, Montpellier

10:00–10:45 AM: Psychedelic therapies - How do they seem to differ from existing treatments in mental health?

David Erritzoe, Imperial College of London

Chair : Anne Claret, Paris

10:45 –11:00 AM: Coffee Break

11:00 –11:45 AM: Mechanisms of psychedelics in the treatment of alcohol dependence - Mickael Naassila, University of Picardy

Chair : Alain Gardier, Orsay

11:45–12:30 AM: Are the neurobiological properties of psychedelics predictive of therapeutic effects in addiction?

Christian Lüscher, University of Geneva

Chair : Marc Gielen, Créteil

12:30–1:30 PM: Lunch Break

PSYCHEDELIC MEDICINE: SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

1:30 –2:00 PM: Processes and challenges in setting up a psilocybin study in France: example of the first French study (PAD)

Amandine Luquiens, CHU Nîmes

Chair : Jérôme Jeanblanc, Amiens

2:00–2:45 PM: Global brain effects of psychedelics and therapeutic implications

Katrin Preller, University Hospital for Psychiatry, Zurich

Chair : Baptiste Fauvel, Paris

2:45–3:30 PM: LSD in the treatment of mood and anxiety disorders

Frederike Holze, Basel University

Chair : Alexandre Alt, Genève

3:30–3:45 PM: Coffee Break

3:45 –4:30 PM: Psilocybin as a catalyst for psychotherapy ? Insights from the German EPIsoDE Trial

Lea Mertens, Central Institute of Mental Health, University of Heidelberg

Chair : Laetitia Vanderijst, Bruxelles

4:30–5:15 PM: Prospects on the use of psychedelic treatments as antidepressant therapy

Guy Goodwin, COMPASS Pathways, London

Chair : Mickael Koslowski, Berlin

5:15–5:30 PM: Closing Remarks, Bureau of the Psychedelic Medicine Section

PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the Afpbn

afpbn
section
médecine
psychédélique



SCANNEZ LE QR CODE POUR VOUS INSCRIRE !

AGENCE PCO : COM'TO EVIDENCE

www.comtoevidence.com



**COM'TO
EVIDENCE**

CONTACT :

Mathias BRACCHETTI-GRANET

Email : contact@comtoevidence.com

Tél. : 33 (0)9 81 25 85 82